Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

STRIDES PHARMA SCIENCE vs MYLAN (US) - Comparison Results

MYLAN (US)
   Change

Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 STRIDES PHARMA SCIENCE   MYLAN
EQUITY SHARE DATA
    STRIDES PHARMA SCIENCE
Mar-23
MYLAN
Dec-18
STRIDES PHARMA SCIENCE/
MYLAN
5-Yr Chart
Click to enlarge
High Rs3923,967-   
Low Rs2632,184-   
Sales per share (Unadj.) Rs408.51,825.4-  
Earnings per share (Unadj.) Rs-25.649.6-  
Cash flow per share (Unadj.) Rs1.4391.3-  
Dividends per share (Unadj.) Rs1.500-  
Avg Dividend yield %0.50-  
Book value per share (Unadj.) Rs242.81,974.7-  
Shares outstanding (eoy) m90.30514.50-   
Bonus / Rights / Conversions 00-  
Price / Sales ratio x0.81.7 47.6%   
Avg P/E ratio x-12.862.0 -20.7%  
P/CF ratio (eoy) x239.67.9 3,049.7%  
Price / Book Value ratio x1.41.6 86.7%  
Dividend payout %-5.90-   
Avg Mkt Cap Rs m29,6031,582,214 1.9%   
No. of employees `000NA35.0 0.0%   
Total wages/salary Rs m7,3200-   
Avg. sales/employee Rs Th026,833.1-  
Avg. wages/employee Rs Th00-  
Avg. net profit/employee Rs Th0728.6-  
INCOME DATA
Net Sales Rs m36,884939,158 3.9%  
Other income Rs m1,3520-   
Total revenues Rs m38,236939,158 4.1%   
Gross profit Rs m830243,019 0.3%  
Depreciation Rs m2,433175,847 1.4%   
Interest Rs m2,61145,170 5.8%   
Profit before tax Rs m-2,86222,002 -13.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-553-3,500 15.8%   
Profit after tax Rs m-2,30925,502 -9.1%  
Gross profit margin %2.225.9 8.7%  
Effective tax rate %19.3-15.9 -121.5%   
Net profit margin %-6.32.7 -230.5%  
BALANCE SHEET DATA
Current assets Rs m31,353524,425 6.0%   
Current liabilities Rs m29,902382,364 7.8%   
Net working cap to sales %3.915.1 26.0%  
Current ratio x1.01.4 76.4%  
Inventory Days Days7184 85.1%  
Debtors Days Days12993 137.8%  
Net fixed assets Rs m31,300182,181 17.2%   
Share capital Rs m903500 180.6%   
"Free" reserves Rs m21,0250-   
Net worth Rs m21,9281,015,998 2.2%   
Long term debt Rs m11,3981,096,588 1.0%   
Total assets Rs m63,7342,725,301 2.3%  
Interest coverage x-0.11.5 -6.5%   
Debt to equity ratio x0.51.1 48.2%  
Sales to assets ratio x0.60.3 167.9%   
Return on assets %0.52.6 18.3%  
Return on equity %-10.52.5 -419.5%  
Return on capital %-0.83.2 -23.6%  
Exports to sales %46.70-   
Imports to sales %00-   
Net fx Rs m17,4420-   
CASH FLOW
From Operations Rs m444195,157 0.2%  
From Investments Rs m3,025-100,875 -3.0%  
From Financial Activity Rs m-2,139-90,916 2.4%  
Net Cashflow Rs m1,3281,617 82.1%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 83.34 Rs / USD

Compare STRIDES PHARMA SCIENCE With: ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  

Compare STRIDES PHARMA SCIENCE With: JAGSON PHAR  DENIS CHEM LAB  ANUH PHARMA  GLAND PHARMA  MEDPLUS HEALTH SERVICES  



Today's Market

Sensex Today Rallies 639 Points | Suzlon Energy Surges 5%, Grasim Industries 4% | 3 Reasons Why Indian Share Market is Rising Sensex Today Rallies 639 Points | Suzlon Energy Surges 5%, Grasim Industries 4% | 3 Reasons Why Indian Share Market is Rising(Closing)

After opening the day on positive note, Indian share markets gained the momentum as the session progressed and ended on firm footing.